| Literature DB >> 21841063 |
Inga Sörensen1, Song Rong, Nathan Susnik, Faikah Gueler, Nelli Shushakova, Melanie Albrecht, Anna-Maria Dittrich, Sibylle von Vietinghoff, Jan Ulrich Becker, Anette Melk, Andrea Bohlmann, Sonja Reingruber, Peter Petzelbauer, Hermann Haller, Roland Schmitt.
Abstract
Renal ischemia-reperfusion contributes to reduced renal allograft survival. The peptide Bβ(15-42), a breakdown product of fibrin, attenuates inflammation induced by ischemia-reperfusion in the heart by competitively blocking the binding of leukocytes to endothelial VE-cadherin, but whether it could improve outcomes in renal transplantation is unknown. Here, we tested the ability of Bβ(15-42) to ameliorate the effects of renal ischemic injury during allogenic kidney transplantation in mice. In our renal transplantation model (C57BL/6 into BALB/c mice), treatment with Bβ(15-42) at the time of allograft reperfusion resulted in significantly improved survival of recipients during the 28-day follow-up (60% versus 10%). Bβ(15-42) treatment decreased leukocyte infiltration, expression of endothelial adhesion molecules, and proinflammatory cytokines. Treatment significantly attenuated allogenic T cell activation and reduced cellular rejection. Moreover, Bβ(15-42) significantly reduced tubular epithelial damage and apoptosis, which we reproduced in vitro. These data suggest that Bβ(15-42) may have therapeutic potential in transplant surgery by protecting grafts from ischemia-reperfusion injury.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21841063 PMCID: PMC3279949 DOI: 10.1681/ASN.2011010031
Source DB: PubMed Journal: J Am Soc Nephrol ISSN: 1046-6673 Impact factor: 10.121